UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes

The UK cost-effectiveness watchdog NICE delivered a resounding "no" Feb. 9 to the use on the National Health Service of Bristol-Myers Squibb's Sprycel (dasatinib) and Novartis' Tasigna (nilotinib) in chronic myeloid leukemia patients who are intolerant to Glivec (imatinib, Gleevec in the U.S.)